ZTS Earnings Date: Nov 5, 2026 — Zoetis Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is ZTS's next earnings date?
Zoetis Inc. (ZTS) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open). The consensus estimate is EPS of $1.51 on revenue of $2.30B.
How did ZTS do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Zoetis Inc. posted EPS of $1.87 versus the $1.85 estimate, a beat of 0.5%. Revenue was $2.47B against a $2.50B estimate. The stock's 1-day post-earnings move was +3.9%.
How much does ZTS stock move after earnings?
ZTS beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.4% (up or down) in the day after earnings.
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 1.85 | 1.87 | +0.54% | $2.47B | ✅ Beat | +3.87% | -1.14% | +2.56% |
| 2026-05-07 | Q1 2026 | 1.61 | 1.53 | -4.97% | $2.26B | ❌ Miss | -21.49% | -33.16% | -28.57% |
| 2026-02-12 | Q4 2025 | 1.40 | 1.48 | +5.71% | $2.39B | ✅ Beat | -2.36% | -1.08% | -10.15% |
| 2025-11-04 | Q3 2025 | 1.62 | 1.70 | +4.94% | $2.40B | ✅ Beat | -13.78% | -17.01% | -15.09% |
| 2025-08-05 | Q2 2025 | 1.62 | 1.76 | +8.64% | $2.50B | ✅ Beat | -3.75% | -1.84% | +0.41% |
| 2025-05-06 | Q1 2025 | 1.40 | 1.48 | +5.71% | $2.22B | ✅ Beat | -5.18% | +2.45% | +6.66% |
| 2025-02-13 | Q4 2024 | 1.34 | 1.40 | +4.48% | $2.32B | ✅ Beat | -5.15% | -9.47% | -7.26% |
| 2024-11-04 | Q3 2024 | 1.45 | 1.58 | +8.97% | $2.39B | ✅ Beat | -3.72% | -2.82% | -2.75% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $2.41B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Dogs and Cats | 67.7% | $1.63B | -4.8% | — | $1.48B | $1.72B | $1.59B |
| Cattle | 16.2% | $390.0M | +21.9% | $399.0M | $358.0M | $320.0M | $399.0M |
| Swine | 4.8% | $117.0M | -1.7% | $128.0M | $111.0M | $119.0M | $111.0M |
| Poultry | 4.8% | $115.0M | +11.7% | $117.0M | $106.0M | $103.0M | $106.0M |
| Fish | 3.4% | $83.0M | +12.2% | $65.0M | $53.0M | $74.0M | $78.0M |
| Horses | 3.1% | $74.0M | +2.8% | $5.80B | $65.0M | $72.0M | $66.0M |
By region
Q2 FY26 · $2.44B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| United States | 51.9% | $1.27B | -6.6% | $1.26B | $1.18B | $1.36B | $1.32B |
| International | 48.1% | $1.17B | +9.6% | $1.04B | $1.01B | $1.07B | $1.05B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.